After Losing Out on Actelion, Deal-Hungry Sanofi Sets Eyes on This Massachusetts Biotech

After being outbid in two high-profile deals over the past six months, Sanofi (NYSE: SNY) is now examining an acquisition of Tesaro, a Massachusetts-based oncology-focused biopharmaceutical company, according to a person claiming to have knowledge of the matter. Morgan Stanley is said to be advising on the potential takeover.

Sanofi recently fell short in its effort to acquire Actelion, a Swiss company that earlier today announced a $30 billion merger agreement with Johnson & Johnson, and last year it was outbid by Pfizer in its pursuit of Medivation, a deal that was valued at $14 billion. Tesaro is smaller in comparison, with a current enterprise value of approximately $7 billion.

Back to news